Anavex gets patent for therapy for CNS conditions

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, announced today it was awarded new U.S. Patent No. 11,661,405 entitled “CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS” from the United States Patent and Trademark Office (USPTO), expanding Anavex’s patent coverage of certain crystal forms of ANAVEX®2-73 (blarcamesine) compositions, processes of preparation, and uses thereof.

Anavex’s newest patent will be expected to remain in force at least until October 2036, not including any patent term extensions. The new patent will expand the coverage of certain ANAVEX®2-73 (blarcamesine) crystals covered by U.S. Patent No. 10,413,519, to methods of their making. The ANAVEX®2-73 (blarcamesine) compound in one of its crystal forms has been used in various preclinical and clinical trials, for a broad range of CNS disorders, including but not limited to, Alzheimer’s disease, Parkinson’s disease, Parkinson’s disease dementia, Rett syndrome, Fragile X syndrome, Infantile spasms, Angelman syndrome

https://finance.yahoo.com/news/anavex-announces-issuance-u-intellectual-113000380.html